National Academies Press: OpenBook

An Assessment of the NIH Women's Health Initiative (1993)

Chapter: Appendix A: Clinical Trial Exclusion Criteria

« Previous: References
Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×

Appendixes

Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
This page in the original is blank.
Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×

A

Clinical Trial Exclusion Criteria (June 28, 1993, WHI Protocol)

  1. Exclusion Criteria for All Components

    1. Competing Risk: Any medical condition associated with predicted survival of less than three years in the judgment of a Clinic physician (e.g., class IV congestive heart failure, obstructive lung disease requiring long-term ventilation or supplemental oxygen in the past, severe chronic liver disease with jaundice or ascites, kidney failure requiring dialysis, sickle cell anemia)

    2. Adherence or Retention Reasons

      • alcoholism

      • other drug dependency

      • mental illness, including severe depression

      • dementia

      • active participant in any other intervention trial where participants are individually randomized to an intervention or control group

  2. Additional Exclusion Criteria for All Clinical Trial Components

    1. Competing Risk

      • invasive cancer of any type in the past 10 years

      • breast cancer at any time (in situ or invasive)

      • any medical condition associated with predicted survival of less than five years in the judgment of a Clinic physician (e.g., class IV congestive heart failure, obstructive lung disease requiring long-term ventilation or supplemental oxygen in the past, severe chronic liver disease with jaundice or ascites, kidney failure requiring dialysis, sickle cell anemia)

SOURCE: Adapted from National Institute of Health's WHI Protocol, June 28, 1993, p.28.

Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
  • baseline mammogram or clinical breast examination findings suspicious of breast cancer (see MOOP for detailed criteria) *

  • acute myocardial infarction in past six months *

  • stroke or transient ischemic attack (TIA) within the past six months *

  • known chronic active hepatitis or severe cirrhosis

  1. Safety reasons

    • severely underweight (BMI < 18 kg/m2 or loss of 15 or more pounds in previous six months)

    • hematocrit < 34% or hemoglobin < 11.5 gm/dl *

    • platelets < 75,000 cells/ml

    • severe hypertension (systolic BP > 200 mmHg or diastolic BP > 105 mmHg)*

    • current use of oral daily corticosteroids for more than six months

  2. Adherence or retention reasons

    • BMI > 40 kg/m2

    • unwilling to participate in baseline or yearly examination components such as yearly mammograms, clinical breast exams, phlebotomy, electrocardiograms, questionnaires and forms; or unable to complete baseline study requirements

  1. Additional Exclusion Criteria for Hormone Replacement Component

    1. Safety reasons

      • endometrial cancer of any stage at any time

      • endometrial hyperplasia at baseline biopsy or endometrial thickness > 5mm via ultrasonography (no recycling)

      • malignant melanoma of any stage at any time

      • non-traumatic thromboembolic event or thromboembolic event associated with estrogen or oral contraceptive use

      • previous osteoporosis-related fracture being treated with hormone replacement therapy

      • history of bleeding disorder serious enough to require transfusion

      • known history of hypertriglyceridemia, or lipemic serum leading to diagnosis of hypertriglyceridemia on baseline blood draw

      • deep vein thrombosis or pulmonary embolism in past six months*

      • currently on anticoagulants *

      • currently on tamoxifen

*

Implies that a woman who is temporarily excluded may be reevaluated for eligibility as appropriate to the excluding condition. If more than six months have elapsed since the woman's first screening visit, however, all baseline and screening activities must be repeated.

Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
  1. Adherence or retention reasons

    • severe menopausal symptoms that would make placebo therapy intolerable to the participant

    • inadequate adherence with placebo run-in (less than 80% of pills taken)

    • unable or unwilling to discontinue use of hormone replacement therapy (women must discontinue current replacement hormone therapy for at least three months in order to be eligible for the HRT)*

    • unwilling to have baseline or yearly endometrial aspirations*

  1. Additional Exclusion Criteria for Dietary Modification Component

    1. Adherence or retention reasons

      • special dietary requirements incompatible with the intervention diet (such as celiac sprue, other malabsorption syndromes, use of MAO inhibitors). Women will be eligible if they are following a diabetic diet or a low salt diet

      • colorectal cancer at any time

      • unable to complete Four-Day Food Record adequately

      • percent of calories from fat estimated to be 34 or less

      • number of main meals prepared out of home ≥ 10 per week

      • type I (insulin-requiring, ketosis-prone) diabetes mellitus

      • gastrointestinal conditions that contraindicate a high fiber diet

  2. Additional Exclusion Criteria for Calcium/Vitamin D Component

    1. Safety reasons

      • History of renal calculi

    2. Adherence or retention reasons

      • unable or unwilling to discontinue use of calcium or vitamin D supplements

      • inadequate adherence with HRT and/or DM trial components during the first year of followup (see Manual of Operations and Procedures for detailed criteria)

Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
This page in the original is blank.
Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
Page 95
Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
Page 96
Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
Page 97
Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
Page 98
Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
Page 99
Suggested Citation:"Appendix A: Clinical Trial Exclusion Criteria." Institute of Medicine. 1993. An Assessment of the NIH Women's Health Initiative. Washington, DC: The National Academies Press. doi: 10.17226/2271.
×
Page 100
Next: Appendix B: U.S. House of Representatives Appropriations COmmittee »
An Assessment of the NIH Women's Health Initiative Get This Book
×
Buy Paperback | $45.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The National Institutes of Health Women's Health Initiative (WHI) is the largest research study ever funded by NIH ($625 million over 14 years) and is designed to test strategies to prevent cardiovascular disease, breast cancer, and osteoporotic fractures—leading causes of death, disability, and decreased quality of life for older women. Although the WHI has already begun, serious questions remain about its design, cost, and the likelihood that it can answer the questions it asks. This book evaluates whether the effort can be justified scientifically.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!